Molecular Type 2 Diabetes Biomarker Identified
|
By LabMedica International staff writers Posted on 23 Feb 2016 |
|
Image: The HiScan SQ scanner (Photo courtesy of Illumina).
Type 2 diabetes mellitus (DM) is an established risk factor for a wide range of vascular diseases, including ischemic stroke (IS) as well as heart attacks, neuropathy and blindness.
Type 2 diabetes is a chronic illness characterized by the presence of elevated blood glucose levels and it accounts for between 80% and 90% of diabetes cases and is one of the major cardiovascular risk factors.
Scientists at the Hospital del Mar Medical Research Institute (Barcelona, Spain) investigated DNA methylation in the blood samples of a cohort of 355 stroke patients using a state-of-the-art technique that allows them to study more than 450,000 methylation points in the genome. In addition, the study compared the methylation profiles of diabetics and non-diabetics as well as their levels of glycosylated hemoglobin (HbA1c), a biomarker that indicates blood glucose levels over the past three months.
DNA samples were extracted from whole peripheral blood collected in 10 mL EDTA tubes. The Chemagic Magnetic Separation Module I system (Chemagen, Baesweiler, Germany) was used for DNA isolation in one cohort, and the Autopure LS (Qiagen, Hilden, Germany) in another. Genome-wide DNA methylation was assessed using the Illumina HumanMethylation450 Beadchip (Illumina Netherlands; Eindhoven, Netherlands) and the arrays were scanned with the Illumina HiScan SQ scanner.
The study was subsequently replicated in two cohorts from independent populations, with 167 and 645 patients respectively, confirming the relationship between Thioredoxin Interacting Protein (TXNIP) methylation, diabetes and glucose level dysfunction. Methylation of TXNIP was inversely and intensely associated with HbA1c levels specifically related to diabetic patients with poor control of glucose levels. The authors concluded that hypomethylation of the TXNIP gene is related to type 2 DM. The inverse relationship between TXNIP methylation and HbA1c values suggests that TXNIP hypomethylation is a consequence of sustained hyperglycemia levels.
Carolina Soriano-Tárraga, PhD, the lead author of the study said, “The methylation of this gene could be used as an early biomarker of dysfunction in the control of glucose levels. We are currently studying the implications and specific role of this gene in diabetes. In the future it could provide a possible therapeutic target for treating diabetes or controlling glucose concentrations.” The study was published originally online on December 7, 2015, in the journal Human Molecular Genetics.
Related Links:
Hospital del Mar Medical Research Institute
Chemagen
Illumina Netherlands
Type 2 diabetes is a chronic illness characterized by the presence of elevated blood glucose levels and it accounts for between 80% and 90% of diabetes cases and is one of the major cardiovascular risk factors.
Scientists at the Hospital del Mar Medical Research Institute (Barcelona, Spain) investigated DNA methylation in the blood samples of a cohort of 355 stroke patients using a state-of-the-art technique that allows them to study more than 450,000 methylation points in the genome. In addition, the study compared the methylation profiles of diabetics and non-diabetics as well as their levels of glycosylated hemoglobin (HbA1c), a biomarker that indicates blood glucose levels over the past three months.
DNA samples were extracted from whole peripheral blood collected in 10 mL EDTA tubes. The Chemagic Magnetic Separation Module I system (Chemagen, Baesweiler, Germany) was used for DNA isolation in one cohort, and the Autopure LS (Qiagen, Hilden, Germany) in another. Genome-wide DNA methylation was assessed using the Illumina HumanMethylation450 Beadchip (Illumina Netherlands; Eindhoven, Netherlands) and the arrays were scanned with the Illumina HiScan SQ scanner.
The study was subsequently replicated in two cohorts from independent populations, with 167 and 645 patients respectively, confirming the relationship between Thioredoxin Interacting Protein (TXNIP) methylation, diabetes and glucose level dysfunction. Methylation of TXNIP was inversely and intensely associated with HbA1c levels specifically related to diabetic patients with poor control of glucose levels. The authors concluded that hypomethylation of the TXNIP gene is related to type 2 DM. The inverse relationship between TXNIP methylation and HbA1c values suggests that TXNIP hypomethylation is a consequence of sustained hyperglycemia levels.
Carolina Soriano-Tárraga, PhD, the lead author of the study said, “The methylation of this gene could be used as an early biomarker of dysfunction in the control of glucose levels. We are currently studying the implications and specific role of this gene in diabetes. In the future it could provide a possible therapeutic target for treating diabetes or controlling glucose concentrations.” The study was published originally online on December 7, 2015, in the journal Human Molecular Genetics.
Related Links:
Hospital del Mar Medical Research Institute
Chemagen
Illumina Netherlands
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i6000
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Latest Clinical Chem. News
- Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
- Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
- Alzheimer’s Biomarkers Identify Faster Cognitive Decline in Adults Over 80
- ADLM Issues Laboratory Guidance for Gender-Diverse Patient Care
- FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
- Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
- Blood Test Detects More High-Risk Prostate Cancers Than PSA
- Rapid Blood Test Aids Diagnosis of Acute Ischemic Stroke
- Blood-Based Alzheimer’s Testing Platform Offers Rapid Results
- Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth
- Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
- Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
- Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging
- Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
- Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Channels
Clinical Chemistry
view channel
Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
Endometriosis occurs when tissue similar to the uterine lining grows outside the womb, triggering inflammation, pain, and scarring. Diagnosis often relies on surgery and, in the UK, takes an average of... Read more
Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
Beckman Coulter Diagnostics has received CE Mark under IVDR for the Access p‑Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms... Read more
Hematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more
Immunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
CE-Marked Blood Assay Automates Tuberculosis Infection Testing
Tuberculosis continues to pose a major global health challenge, with an estimated 10.7 million people falling ill and 1.23 million deaths in 2024. Roughly one quarter of the world’s population is believed... Read more
Genomic Surveillance Algorithm Improves Early Detection of Emerging Variants
Genomic surveillance is essential for detecting viral variants before they spread widely, yet many public health systems face high costs, uneven capacity, and computational barriers. Existing analytic... Read more
Rapid Gastrointestinal PCR Panels Deliver One-Hour Results
Acute infectious gastroenteritis remains a major cause of illness worldwide, especially in young children, older adults, and immunocompromised patients. Nonspecific symptoms such as diarrhea, vomiting,... Read more
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read morePathology
view channel
New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
Recurrent breast cancer remains a persistent driver of morbidity and retreatment, and current risk stratification often depends on genomic assays that are costly and slow. Waiting weeks for results can... Read more
EBV Status Helps Predict Survival in Primary CNS Lymphoma
Primary central nervous system lymphoma is a rare malignancy in which tumors arise in the brain and, less often, the spinal cord, eyes, or cerebrospinal fluid. Outcomes are especially variable when the... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more
